IN THE CLAIMS:

Please cancel claims 8-10 and 15-19 without prejudice Please enter the attached listing of claims into the application. This listing of claims replaces all prior listing of claims in the application.

LISTING OF CLAIMS

- 1. (Previously Presented) A compound selected from any one of 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:1); 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂ (SEQ ID NO:2); 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Asp-NH₂ (SEQ ID NO:3); 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Thr-NH₂ (SEQ ID NO:4); 4-amino-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂ (SEQ ID NO:5); 4-amino-3-iodo-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:6); 4-amino-3-iodo-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:8); 4-amino-3-iodo-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂ (SEQ ID NO:8); 4-amino-3-iodo-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:9); and D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:10).
- 2. (Previously Presented) The compound of claim 1, wherein the compound comprises a di- or polyiodinated aromatic modification of a Tyr at position 3 of SEQ ID NOs:1-10.
- 3. (Previously Presented) The compound of claim 1, wherein a radioactive element is linked to the compound.
- 4. (Original) The compound of claim 3, wherein the radioactive element is selected from the group consisting of ¹⁸⁸Re, ¹⁸⁶Re, scandium-47, copper-67, gallium-72, yttrium-90, iodine-125, iodine-131, samarium-153, gadolinium-159, dysprosium-165, holmium-166, ytterbium-175, lutetium-177, rhenium-186, rhenium-188, astatine-211 and bismuth-212.

- 5. (Previously Presented) The compound of claim 1, wherein the compound is linked to a cytotoxic molecule.
- 6. (Original) The compound of claim 5, wherein the cytotoxic molecule is selected from the group consisting of paclitaxel, doxorubicin or camptothecin.
- 7. (Original) The compound of claim 1, further comprising a pharmaceutically acceptable carrier.
- 8-10. (Cancelled).
- 11. (Original) A compound which selectively binds to SS receptor 2 (SST2) and/or SS receptor 5 (SST5), wherein the compound has a structure selected from the group consisting of (4-Amino)-D-Phe-c [Cys-Tyr-D-Trp-Lys-Val-Cys] –Thr-NH₂, (4-Amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp- NH₂, (4-Amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Trp-Lys-Val-Cys]-D-Asp-NH₂, (4-Amino)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂, (4-Amino-3-iodo)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂, (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂, (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂, (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂, and D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂.
- 12. (Original) The compound of claim 11, further comprising a radioactive nuclide or a conjugating agent for linking to a cytotoxin.
- 13. (Previously Presented) A pharmaceutical composition comprising a mixture of a compound of claim 11 and at least one pharmaceutically acceptable carrier.
- 14. (Previously Presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

15-19. (Cancelled).